Dermatology Advisor2d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Medscape11d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
Medical Dialogues7d
Psoriasis Patients at Higher Risk of Metabolic and Cardiovascular Conditions, Study Shows
The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
BioSpace6d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Physician's Weekly2d
Using Targeted Interventions to Elevate QOL & Symptom Control in Plaque Psoriasis
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
Fierce Biotech3d
Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...
Managed Healthcare Executive6d
FDA Approves Tremyfa to Treat Active Crohn’s Disease
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...